Skip to main content

15.09.2017 | Original Article | Ausgabe 1/2018

Comparative Clinical Pathology 1/2018

Pulmonary tuberculosis: could tumor markers CA 15-3 and CA 125 be useful for diagnosis and evaluation of response to therapy?

Comparative Clinical Pathology > Ausgabe 1/2018
Ehsan Rizk, Ehab Badran Rakha, Azema Abd El-Rahman, Walaa Othman Elshabrawy, Niveen Saudy


Diagnosis and treatment evaluation of pulmonary tuberculosis (PTB) are time-consuming, so a non-conventional approach should be considered. Our study investigates the utility of CA125 and CA15-3 in differentiation of PTB from other pulmonary infections and prediction of response to antituberculous drugs. A prospective case control study was carried out on 69 patients: group A: 42 PTB and group B (control): 27 non-PTB patients. All patients were subjected to clinical, radiological, microbiological, and quantitative measurement of serum levels of CA125 and CA15-3 by ELIZA at time of diagnosis. Gp-A patients were ZN and culture positive for TB. Antituberculous susceptibility of Mycobacterium isolates was performed by proportional method. Two months after therapy, ZN examination and CA125 and CA15-3 levels were performed. Pretreatment levels of CA125 and CA15-3 in TB patients were significantly higher than both control groups (P = < 0.001 for both markers) and the posttreatment levels (P = 0.001 for both markers). Their sensitivity and specificity were CA125 (95.2 and 81.5%) and CA15-3 (66.7 and 77.8%). CA125 area under curve was significantly higher than that of CA15-3 (0.933, 0.736, P = 0.005). Only resistant strains to isoniazid and ethambutol showed significantly higher levels of CA125 when compared to sensitive strains (P = 0.024). Regression analysis showed that higher CA125 and CA15-3 levels were considered as predictors of TB infection, while higher CA125 was a prognostic factor for prediction of resistance to TB treatment. Serum CA125 and CA15-3 levels can be used as markers for prediction of TB infection and evaluation of responses to antituberculous treatments.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Comparative Clinical Pathology 1/2018 Zur Ausgabe